ALLMedicine™ Alagille Syndrome Center

Aug 4th, 2022 - Alagille syndrome (ALGS, OMIM 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000~1:50000. Most patients with ALGS have hypercholesterolemia. In severe cases, multiple xanthomas can be seen, an...

Aug 4th, 2022 - BACKGROUND Alagille syndrome (AGS) is a rare genetic disease characterized by 5 typical features: peculiar facial anomaly, posterior embryotoxon, chronic cholestasis, butterfly-like vertebral-arch defects, and cardiovascular malformations. AGS in ...

Jul 23rd, 2022 - Alagille syndrome (ALGS) is a complex heterogenous disease with a wide array of clinical manifestations in association with cholestatic liver disease. Major clinical and genetic advancements have taken place since its first description in 1969. Ho...

Jul 19th, 2022 - This is an open label study where all participants will receive maralixibat treatment.

Jun 16th, 2022 - Pediatric Liver Transplant Outcomes in Alagille Syndrome: A Linked Database Analysis.|2022|Black K,Ziogas IA,Thurm C,Hall M,Thor Hafberg E,|surgery,adverse effects,

Aug 4th, 2022 - Alagille syndrome (ALGS, OMIM 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000~1:50000. Most patients with ALGS have hypercholesterolemia. In severe cases, multiple xanthomas can be seen, an...

Jul 19th, 2022 - This is an open label study where all participants will receive maralixibat treatment.

Mar 31st, 2022 - Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Mar 10th, 2022 - Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Nov 19th, 2021 - The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed participation in a core LUM001 treatment protocol...

May 23rd, 2022 - Pruritus is a prime clinical expression of cholestatic diseases in children and adults. In my clinical experience, there was no more poignant depiction of the ravages of cholestatic pruritus than that of an 11-year-old girl with Alagille syndrome ...

Sep 29th, 2021 - Mirum Pharmaceuticals Inc said its drug became the first U.S. approved therapy for treating itching in patients with rare liver disorder Alagille syndrome (ALGS), and would be available for distribution immediately. Shares of the company were brie...

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Oct 11th, 2017 - WASHINGTON, DC — Advances in the treatment of nonalcoholic steatohepatitis (NASH) — including results from a phase 2 trial of a liver-targeted selective inhibitor of acetyl-CoA carboxylase — will be in the spotlight here at The Liver Meeting 2017:...

Apr 8th, 2016 - Intrahepatic Cholestasis Neonatal cholestasis results from a heterogeneous group of intrahepatic disorders caused by mutations in several genes.[28] Recent advances in the understanding of the molecular basis of genetic cholestatic syndromes, such...